Q1 2025 · 13F-HR
Cormorant Asset Management, LPholdings as filed
Filed 2025-05-15 · accession 0001583977-25-000005
$1.33B
Reported value
44
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $331.9M | 25.0% | 8,494,151 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $90.2M | 6.79% | 4,101,992 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $69.1M | 5.20% | 2,000,000 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $68.9M | 5.18% | 1,050,000 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $66.1M | 4.97% | 1,745,000 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $57.8M | 4.35% | 2,825,000 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $54.0M | 4.06% | 2,000,000 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $45.1M | 3.39% | 8,325,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $40.1M | 3.01% | 525,000 | Common | SOLE |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $38.2M | 2.87% | 1,059,331 | Common | SOLE |
| G4444H101 | BBOT | HELIX ACQUISITION CORP II | $32.9M | 2.47% | 2,909,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $32.5M | 2.45% | 2,261,600 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $31.1M | 2.34% | 740,000 | Common | SOLE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC | $29.5M | 2.22% | 2,940,921 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $29.2M | 2.19% | 250,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $23.0M | 1.73% | 1,466,460 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $22.2M | 1.67% | 2,009,482 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $21.1M | 1.59% | 1,350,000 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $20.5M | 1.55% | 400,000 | Common | SOLE |
| 82835W108 | SPRY | ARS PHARMACEUTICALS INC | $20.1M | 1.51% | 1,600,000 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $20.1M | 1.51% | 600,000 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $19.0M | 1.43% | 775,000 | Common | SOLE |
| 14179K101 | CRGX | CARGO THERAPEUTICS INC | $13.8M | 1.03% | 3,381,277 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $13.3M | 1.00% | 2,130,000 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $13.2M | 0.99% | 2,147,396 | Common | SOLE |
| 21833P301 | CRBP | CORBUS PHARMACEUTICALS HLDGS | $12.6M | 0.95% | 2,375,000 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $11.8M | 0.89% | 400,000 | Common | SOLE |
| 59267L107 | — | METSERA INC | $10.9M | 0.82% | 400,000 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $10.4M | 0.78% | 2,323,595 | Common | SOLE |
| 09077V100 | BIOA | BIOAGE LABS INC | $9.9M | 0.74% | 2,629,529 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $7.9M | 0.60% | 150,000 | Common | SOLE |
| 68277Q105 | OKUR | ONKURE THERAPEUTICS INC | $7.9M | 0.59% | 1,837,739 | Common | SOLE |
| 09077A106 | BMEA | BIOMEA FUSION INC | $7.6M | 0.57% | 3,570,872 | Common | SOLE |
| 500946108 | KRRO | KORRO BIO INC | $6.6M | 0.50% | 380,303 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $6.6M | 0.50% | 175,000 | Common | SOLE |
| 002942100 | AARD | AARDVARK THERAPEUTICS INC | $6.0M | 0.45% | 800,189 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $5.2M | 0.39% | 700,000 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $5.1M | 0.38% | 250,000 | CALL | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $4.9M | 0.37% | 250,000 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $4.0M | 0.30% | 150,000 | CALL | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $4.0M | 0.30% | 3,000,000 | Common | SOLE |
| 483119202 | KALAEUR | KALA BIO INC | $3.5M | 0.26% | 603,027 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $1.7M | 0.13% | 254,161 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $240,400 | 0.02% | 10,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.